Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Acquired Immunodeficiency Syndrome

Gange SJ, Kitahata MM, Saag MS, et al. "Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)." Int J Epidemiol. 2007;36(2):294-301.
Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. "Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177." J. Acquir. Immune Defic. Syndr.. 2010;54(4):e7-9.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Tenorio AR, Jiang H, Zheng Y, et al. "Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115." AIDS Res. Hum. Retroviruses. 2009;25(2):135-9.
Castillo-Mancilla JR, Cohn SE, Krishnan S, et al. "Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials." HIV Clin Trials. 2014;15(1):14-26.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
Dykes C, A Mukherjee L, Bosch RJ, Connick E, Volberding PA, Demeter LM. "Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371." J. Acquir. Immune Defic. Syndr.. 2010;55(1):132-4.
Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.
Motsinger AA, Ritchie MD, Shafer RW, et al. "Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study." Pharmacogenet. Genomics. 2006;16(11):837-45.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
George E, Noël F, Bois G, et al. "Antiretroviral therapy for HIV-1-infected children in Haiti." J. Infect. Dis.. 2007;195(10):1411-8.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Wohl DA, Kendall MA, Feinberg J, et al. "The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit." PLoS ONE. 2013;8(11):e78676.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Abbas UL, Anderson RM, Mellors JW. "Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings." J. Acquir. Immune Defic. Syndr.. 2006;41(5):632-41.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Mugavero MJ, Pence BWells, Whetten K, et al. "Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort." AIDS Patient Care STDS. 2007;21(9):681-90.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Huang X-L, Fan Z, Borowski L, Rinaldo CR. "Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity." J. Leukoc. Biol.. 2008;83(6):1530-40.
Verma A, Bradford Y, Verma SS, et al. "Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2017;27(3):101-111.
L Wheat J, Connolly P, Smedema M, et al. "Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole." J. Antimicrob. Chemother.. 2006;57(6):1235-9.
Swindells S, Jiang H, A Mukherjee L, Winters M, Bosch RJ, Katzenstein D. "Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(2):79-88.

Pages